{"id":"NCT00883337","sponsor":"Sanofi","briefTitle":"A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis","officialTitle":"A Multi-center, Randomized, Parallel-group, Rater-blinded Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis Plus a Long Term Extension Period","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-04","primaryCompletion":"2011-09","completion":"2015-05","firstPosted":"2009-04-17","resultsPosted":"2012-11-06","lastUpdate":"2016-06-13"},"enrollment":324,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Interferon β-1a","otherNames":["Rebif®"]},{"type":"DRUG","name":"Teriflunomide","otherNames":["HMR1726"]}],"arms":[{"label":"Teriflunomide 7 mg / 14 mg","type":"EXPERIMENTAL"},{"label":"Teriflunomide 14 mg / 14 mg","type":"EXPERIMENTAL"},{"label":"IFN-β-1a / 14 mg","type":"ACTIVE_COMPARATOR"}],"summary":"Primary objective was to assess the effectiveness evaluated by the time to failure of two doses of teriflunomide in comparison to interferon beta-1a in participants with relapsing Multiple Sclerosis \\[MS\\].\n\nSecondary objectives were:\n\n* To assess the effect of the two doses in comparison to interferon beta-1a on:\n\n  * Frequency of relapses,\n  * Fatigue,\n  * Participant's satisfaction with treatment.\n* To evaluate the safety and tolerability of the two doses in comparison to interferon beta-1a.\n\nThe study consisted of a core treatment period with a common end date defined as 48 weeks after randomization of the last participant, followed by an optional long-term extension treatment period until teriflunomide is commercially available in accordance with local regulations.","primaryOutcome":{"measure":"Core Treatment Period: Overview of Failures","timeFrame":"Core treatment period between 48 and 118 weeks depending on when the participant was enrolled","effectByArm":[{"arm":"Teriflunomide 7 mg","deltaMin":53,"sd":null},{"arm":"Teriflunomide 14 mg","deltaMin":42,"sd":null},{"arm":"IFN-β-1a","deltaMin":44,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":12},"locations":{"siteCount":54,"countries":["Belgium","Canada","Czechia","France","Germany","Greece","Hungary","Italy","Poland","Spain","Switzerland","Tunisia","United Kingdom"]},"refs":{"pmids":["24126064","33023488"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":110},"commonTop":["Nasopharyngitis","Headache","Diarrhoea","Alanine aminotransferase increased","Influenza like illness"]}}